Cart
sales@molnova.com
Pyrroloquinoline quinone
CAS No. 72909-34-3
Pyrroloquinoline quinone( —— )
Catalog No. M20485 CAS No. 72909-34-3
Pyrroloquinoline quinone (PQQ) as a well-known redox enzyme cofactor PQQ can protect NS/PCs against glutamate toxicity associated with ROS-mediated mitochondrial pathway
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | 30 | In Stock |
|
| 50MG | 40 | In Stock |
|
| 100MG | 56 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 128 | In Stock |
|
| 1G | 183 | In Stock |
|
Biological Information
-
Product NamePyrroloquinoline quinone
-
NoteResearch use only, not for human use.
-
Brief DescriptionPyrroloquinoline quinone (PQQ) as a well-known redox enzyme cofactor PQQ can protect NS/PCs against glutamate toxicity associated with ROS-mediated mitochondrial pathway
-
DescriptionPyrroloquinoline quinone (PQQ) as a well-known redox enzyme cofactor PQQ can protect NS/PCs against glutamate toxicity associated with ROS-mediated mitochondrial pathway.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number72909-34-3
-
Formula Weight330.21
-
Molecular FormulaC14H6N2O8?
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?H2O : 1 mg/mL (3.03 mM)
-
SMILESOC(=O)c1cc2c([nH]1)-c1c(cc(nc1C(=O)C2=O)C(O)=O)C(O)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Guan S Xu J Guo Y et al. Pyrroloquinoline quinone against glutamate-induced neurotoxicity in cultured neural stem and progenitor cells[J]. International Journal of Developmental Neuroscience 2015 42:37-45.
molnova catalog
related products
-
PH-46A
A potent, first-in-class, oral small-molecule agent for the treatment of inflammatory bowel diseases.
-
α-Terpinene
α-Terpinene is a terpenoidhas acaricidal antiprotozoal and antioxidant properties.
-
BV02
BV02 is an inhibitor of 14-3-3 protein-protein interactions and can be used in studies about the treatment of chronic myeloid leukemia. BV02 disrupts hematopoietic cells expressing the IM-resistant T315I mutation and the IM-sensitive wild-type Bcr-Abl.
